CUA Educational Content

The Role of ADT Across the Continuum of Prostate Cancer

EDITORTIAL COMMITTEE: Fred Saad, Gulia Delouya, Shaun Goodman, Bobby Shayegan

By participating in this program, health care providers can expect to:

  • describe the hormonal therapy continuum for prostate cancer, including the role of androgen deprivation therapy (ADT) as the backbone of therapy
  • explain the rationale for earlier treatment with hormonal therapies in patients with high-risk prostate cancer
  • discuss strategies to minimize the potential cardiovascular (CV) side effects of ADT
  • review recent advances in the treatment of advanced prostate canced
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.

​This program was made possible with financial support from Tolmar.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy